ScinoPharm announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia, a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012.
URL: http://www.news-medical.net/news/20120719/ScinoPharm-to-offer-commercial-manufacturing-of-topiramate-API-for-VIVUS-Qsymia.aspx
No comments:
Post a Comment